Table 2 Characteristics of study subjects in Non-incident Alzheimer’s disease group and incident Alzheimer’s disease group.
Non-incident Alzheimer’s disease | Incident Alzheimer’s disease | |
|---|---|---|
No. of subjects (%) | 178,672 (93.1) | 13,133 (6.9) |
Sex, male | 83,404 (46.7) | 4,363 (33.2) |
Age (years) | 66.5 ± 5.8 | 70.6 ± 6.5 |
Level of income | ||
Medical aid | 21,163 (11.8) | 3,313 (25.2) |
4/10 percentile | 48,822 (27.3) | 3,147 (24.0) |
8/10 percentile | 61,420 (34.4) | 3,609 (27.5) |
10/10 percentile | 47,267 (26.5) | 3,064 (23.3) |
Person-year (day) | 3184.4 ± 220.4 | 2755.3 ± 312.9 |
Strong ACs * | 26.7 ± 59.4 | 38.6 ± 80.3 |
0–9 | 90,145 (50.5) | 5,863 (44.6) |
10–49 | 66,541 (37.2) | 4,714 (35.9) |
50–119 | 14,353 (8.0) | 1,503 (11.4) |
≥120 | 7,633 (4.3) | 1,053 (8.0) |
Weak ACs * | 68.1 ± 136.9 | 76.2 ± 140.1 |
0–29 | 109,205 (61.1) | 7,217 (55.0) |
30–119 | 40,299 (22.6) | 3,451 (26.3) |
120–299 | 19,634 (11.0) | 1,693 (13.0) |
≥300 | 9,534 (5.3) | 772 (5.9) |
Antihistamines* | 15.3 ± 30.6 | 19.2 ± 38.6 |
Antidepressants* | 5.7 ± 36.6 | 10.2 ± 53.4 |
Urinary antimuscarinics* | 2.7 ± 17.9 | 4.3 ± 22.5 |
Other non-anticholinergic agents that can impair cognitive function† | 12.6 ± 34.9 | 20.0 ± 45.5 |
Charlson Comorbidity Index | ||
0–1 | 67,710 (37.9) | 4,119 (31.4) |
2–3 | 85,540 (47.9) | 6,756 (51.4) |
≥4 | 25,422 (14.2) | 2,258 (17.2) |
Medical histories | ||
Hypertension | 38,381 (21.5) | 2,566 (19.5) |
Cardiovascular disease | 4,035 (2.3) | 344 (2.6) |
Myocardial infraction | 1,720 (1.0) | 1,152 (1.1) |
Diabetes mellitus | 14,820 (8.3) | 1,152 (8.8) |
Parkinson’s disease | 131 (0.1) | 26 (0.2) |
Sleep disorder | 364 (0.2) | 41 (0.3) |
Dizziness | 2,490 (1.4) | 246 (1.9) |
Genitourinary disease | 4,326 (2.4) | 289 (2.2) |
Epilepsy | 200 (0.1) | 24 (0.2) |
Neuralgia | 4,424 (2.5) | 374 (2.9) |
Skin disease | 4,790 (2.7) | 337 (2.6) |
